DOCSLIB.ORG

2021 ECCMID | 00656 in Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2021 ECCMID | 00656 in Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales IHMA In Vitro Activities of Ceftazidime-avibactam and Comparator Agents against Enterobacterales and 2122 Palmer Drive 00656 Schaumburg, IL 60173 USA Pseudomonas aeruginosa from Israel Collected Through the ATLAS Global Surveillance Program 2013-2019 www.ihma.com M. Hackel1, M. Wise1, G. Stone2, D. Sahm1 1IHMA, Inc., Schaumburg IL, USA, 2Pfizer Inc., Groton, CT USA Introduction Results Results Summary Avibactam (AVI) is a non-β- Table 1 Distribution of 2,956 Enterobacterales from Israel by species Table 2. In vitro activity of ceftazidime-avibactam and comparators agents Figure 2. Ceftazidime and ceftazidime-avibactam MIC distribution against 29 . Ceftazidime-avibactam exhibited a potent lactam, β-lactamase inhibitor against Enterobacterales and P. aeruginosa from Israel, 2013-2019 non-MBL carbapenem-nonsusceptible (CRE) Enterobacterales from Israel, antimicrobial activity higher than all Organism N % of Total mg/L that can restore the activity of Organism Group (N) %S 2013-2019 comparator agents against all Citrobacter amalonaticus 2 0.1% MIC90 MIC50 Range ceftazidime (CAZ) against Enterobacterales (2956) 20 Enterobacterales from Israel (MIC90, 0.5 Citrobacter braakii 5 0.2% Ceftazidime-avibactam 99.8 0.5 0.12 ≤0.015 - > 128 Ceftazidime Ceftazidime-avibactam organisms that possess Class 18 mg/L; 99.8% susceptible). Citrobacter freundii 96 3.2% Ceftazidime 70.1 64 0.25 ≤0.015 - > 128 A, C, and some Class D β- Cefepime 71.8 > 16 ≤0.12 ≤0.12 - > 16 16 . Susceptibility to ceftazidime-avibactam lactmase enzymes. This study Citrobacter gillenii 1 <0.1% Meropenem 98.8 0.12 ≤0.06 ≤0.06 - > 8 increased to 100% for the Enterobacterales Amikacin 95.4 8 2 ≤0.25 - > 32 14 examined the in vitro activity Citrobacter koseri 123 4.2% when MBL-positive isolates were removed Colistin (n=2544)* 82.2 > 8 0.5 ≤0.06 - > 8 12 of CAZ-AVI and comparators Citrobacter murliniae 1 <0.1% Piperacillin-tazobactam 80.4 32 2 ≤0.12 - > 64 from analysis. against Enterobacterales and Enterobacterales, MBL-negative (2948) N 10 . 100% of MBL-negative, meropenem- Citrobacter sedlakii 4 0.1% Ceftazidime-avibactam 100 0.5 0.12 ≤0.015 - 8 Pseudomonas aeruginosa Ceftazidime 70.3 64 0.25 ≤0.015 - > 128 8 nonsusceptible Enterobacterales isolates Enterobacter asburiae 13 0.4% Cefepime 72.0 > 16 ≤0.12 ≤0.12 - > 16 collected in Israel through the 6 (CRE) were susceptible to ceftazidime- Enterobacter cloacae 211 7.1% Meropenem 99.0 0.12 ≤0.06 ≤0.06 - > 8 ATLAS global surveillance Amikacin 95.5 8 2 ≤0.25 - > 32 avibactam (MIC , 4 mg/L). 4 90 program from 2013 to 2019. Enterobacter cloacae complex 1 <0.1% Colistin (n=2536)* 82.3 > 8 0.5 ≤0.06 - > 8 . Similarly, 100% of KPC-producing Piperacillin-tazobactam 80.5 32 2 ≤0.12 - > 64 2 Enterobacter kobei 4 0.1% CRE, MBL-negative (29) Enterobacterales isolates were susceptible to Ceftazidime-avibactam 100 4 1 0.12 - 8 0 Enterobacter ludwigii 1 <0.1% ceftazidime-avibactam (MIC90, 4 mg/L). Ceftazidime 0 > 128 > 128 16 - > 128 0.12 0.25 0.5 1 2 4 8 16 32 64 > 64 Enterobacter sp. 5 0.2% Cefepime 6.9 > 16 > 16 0.25 - > 16 . Ceftazidime-avibactam also showed greater Meropenem 0 > 8 > 8 4 - > 8 MIC (mg/L) activity than all comparators against P. Escherichia coli 877 29.7% Amikacin 44.8 > 32 16 0.5 - > 32 Dashed line represents the EUCAST 2020 breakpoint of 8 mg/L for ceftazidime-avibactam aeruginosa isolates from Israel (MIC , 4 Klebsiella aerogenes 147 5.0% Colistin (n=23) * 91.3 2 0.5 0.12 - > 8 90 Piperacillin-tazobactam 0 > 64 > 64 32 - > 64 Figure 3. Ceftazidime and ceftazidime-avibactam MIC distribution against 21 mg/L; 98.5% susceptible). Against only the Klebsiella oxytoca 152 5.1% Enterobacterales, KPC-positive (21) Ceftazidime-avibactam 100 4 1 0.12 - 4 KPC-positive Enterobacterales from Israel, 2013-2019 meropenem non-susceptible P. aeruginosa Klebsiella pneumoniae 809 27.4% Ceftazidime 0 > 128 > 128 16 - > 128 16 subset, the activity remained very good as Klebsiella variicola 9 0.3% Cefepime 0 > 16 > 16 0.25 - > 16 Ceftazidime Ceftazidime-avibactam 94.5% of the isolates were susceptible with Methods Meropenem 0 > 8 > 8 4 - > 8 14 Morganella morganii 84 2.8% Amikacin 38.1 > 32 32 0.5 - > 32 only the last resort agent, colistin, exhibiting A total of 2,956 non-duplicate, Colistin (n=16)* 87.5 4 0.5 0.12 - > 8 Pluralibacter gergoviae 1 <0.1% Piperacillin-tazobactam 0 > 64 >64 > 64 - > 64 12 higher activity (96.3% susceptible). clinically isolated Entero- Proteus hauseri 14 0.5% Escherichia coli (877) bacterales and 820 P. Ceftazidime-avibactam 100 0.25 0.12 ≤0.015 - 8 10 Proteus mirabilis 156 5.3% Ceftazidime 72.1 32 0.25 ≤0.015 - > 128 aeruginosa were collected Cefepime 73.9 > 16 ≤0.12 ≤0.12 - > 16 N 8 from five sites in Israel during Proteus penneri 3 0.1% Meropenem 99.7 0.06 0.03 ≤0.06 - > 8 Amikacin 95.4 8 2 0.5 - > 32 Conclusions 2013 to 2019. Susceptibility Proteus vulgaris 68 2.3% 6 Colistin (n=734)* 99.7 1 0.25 ≤0.06 - > 8 Ceftazidime-avibactam demonstrated potent in testing was done using broth Providencia rettgeri 10 0.3% Piperacillin-tazobactam 86.9 16 2 ≤0.25 - > 64 4 Klebsiella pneumoniae (809) vitro activity against Enterobacterales and P. microdilution according to Providencia stuartii 64 2.2% Ceftazidime-avibactam 100 0.5 0.12 ≤0.015 - 8 2 aeruginosa collected in Israel. For infections CLSI guidelines (1) and Raoultella ornithinolytica 3 0.1% Ceftazidime 49.7 128 2 ≤0.015 - > 128 Cefepime 50.6 > 16 1 ≤0.12 - > 16 caused by P. aeruginosa and Enterobacterales interpreted using EUCAST 0 Serratia marcescens 92 3.1% Meropenem 97.4 0.12 ≤0.06 ≤0.06 - > 8 that are MBL-negative, ceftazidime-avibactam 2021 breakpoints (2). CAZ-AVI Amikacin 93.2 8 1 0.5 - > 32 0.12 0.25 0.5 1 2 4 8 16 32 64 > 64 Total 2956 100% Colistin (n=706)* 99.2 1 0.5 ≤0.06 - > 8 offers a compelling therapeutic alternative to was tested with a fixed MIC (mg/L) Piperacillin-tazobactam 61.9 > 64 8 0.5 - > 64 other agents like colistin and meropenem. concentration of 4 mg/L AVI. Enterobacter spp. (235) Dashed line represents the EUCAST 2020 breakpoint of 8 mg/L for ceftazidime-avibactam Organisms non-susceptible to Figure 1. Ceftazidime and ceftazidime-avibactam MIC distribution against Ceftazidime-avibactam 98.7 1 0.25 ≤0.015 - 64 2,956 Enterobacterales from Israel, 2013-2019 Ceftazidime 66.0 128 0.5 0.06 - > 128 Figure 4. Ceftazidime and ceftazidime-avibactam MIC distribution against 820 meropenem were screened Cefepime 74.0 16 ≤0.12 ≤0.12 - > 16 for acquired beta-lactamases 1200 Meropenem 97.5 0.12 ≤0.06 ≤0.06 - > 8 P. aeruginosa from Israel, 2013-2019 Amikacin 98.7 4 1 0.5 - > 32 by PCR, followed by Sanger Ceftazidime Ceftazidime-avibactam 450 Colistin (n=210)* 93.3 1 0.5 ≤0.06 - > 8 Ceftazidime Ceftazidime-avibactam sequencing (3). 1000 Piperacillin-tazobactam 71.1 > 64 2 ≤0.25 - > 64 400 References Pseudomonas aeruginosa (820) 1. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow aerobically. 11th ed. CLSI standard M07. Wayne, PA: Clinical 800 Ceftazidime-avibactam 98.5 4 2 ≤0.015 - 32 350 Ceftazidime** 83.8 32 2 0.12 - > 128 and Laboratory Standards Institute; 2018. 2. The European Committee on Antimicrobial Susceptibility Testing. Cefepime** 86.0 16 2 ≤0.12 - > 32 300 Breakpoint tables for interpretation of MICs and zone diameters. Version Meropenem 82.2 8 0.5 0.015 - > 8 600 11.0, 2021. http://www.eucast.org. N Amikacin 97.4 8 4 ≤0.25 - > 64 250 N 3. Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Colistin (n=760)* 97.9 2 1 0.12 - 4 200 Biedenbach DJ, Sahm, DF. 2015. Trends in susceptibility of Escherichia coli 400 Piperacillin-tazobactam** 78.5 > 128 8 ≤0.12 - > 128 from intra-abdominal infections to ertapenem and comparators in the United Pseudomonas aeruginosa, MEM-NS (146) 150 States according to data from the SMART program, 2009 to 2013. Ceftazidime-avibactam 94.5 8 4 1 - 32 Antimicrob Agents Chemother 59:3606-3610. 200 Ceftazidime** 63.0 128 8 1 - > 128 100 Cefepime** 60.3 32 8 1 - > 32 0 Meropenem 0 > 8 8 4 - > 8 50 Amikacin 91.1 16 4 0.5 - > 64 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 > 64 Colistin (n=134)* 96.3 2 1 0.25 - 4 0 MIC (mg/L) Piperacillin-tazobactam** 50.7 > 128 16 4 - > 128 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 > 64 Disclosures %S, percent susceptible defined using EUCAST 2021 breakpoints; CRE, carbapenem resistant This study was sponsored by Pfizer. IHMA received financial support from Enterobacterales based on meropenem nonsusceptibility (MIC ≥4mg/L); MEM, meropenem; NS, non- MIC (mg/L) Pfizer in connection with the study and the development of this poster. MW, Dashed line represents the EUCAST 2020 breakpoint of 8 mg/L for ceftazidime-avibactam susceptible. MBL, metallo-β-lactamase MH, and DS are employees of IHMA. GS is an employee of Pfizer. *colistin was not tested in 2013 Dashed line represents the EUCAST 2020 breakpoint of 8 mg/L for ceftazidime-avibactam **% “susceptible, increased exposure” is given Presented at ECCMID 2021, July 9-12, 2021 Online.
Load more

Recommended publications
  • Effects of Zinc and Menthol-Based Diets on Co-Selection of Antibiotic Resistance Among E
    animals Article Effects of Zinc and Menthol-Based Diets on Co-Selection of Antibiotic Resistance among E. coli and Enterococcus spp. in Beef Cattle Sarah A. Murray 1, Raghavendra G. Amachawadi 2 , Keri N. Norman 3 , Sara D. Lawhon 1, Tiruvoor G. Nagaraja 4 , James S. Drouillard 5 and Harvey M. Scott 1,* 1 Department of Veterinary Pathobiology, Texas A&M University, College Station, TX 77843, USA; [email protected] (S.A.M.); [email protected] (S.D.L.) 2 Department of Clinical Sciences, Kansas State University, Manhattan, KS 66506, USA; [email protected] 3 Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX 77843, USA; [email protected] 4 Department of Diagnostic Medicine and Pathobiology, Kansas State University, Manhattan, KS 66506, USA; [email protected] 5 Department of Animal Sciences and Industry, Kansas State University, Manhattan, KS 66506, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-(979)-847-6197 Simple Summary: As antibiotic resistance increases globally, alternatives to antibiotics are increas- ingly being investigated as growth promoters, as well as preventive and therapeutic agents, partic- ularly in agriculture. Equally important is the need for investigation into the effects of antibiotic Citation: Murray, S.A.; Amachawadi, alternatives on antibiotic resistance and particularly their risk for co-selection. In this study, we R.G.; Norman, K.N.; Lawhon, S.D.; explored the prevalence of antibiotic-resistant Escherichia coli and Enterococcus spp. in cattle fed zinc, Nagaraja, T.G.; Drouillard, J.S.; Scott, menthol or a combination of the two.
    [Show full text]
  • Potential for and Distribution of Enzymatic Biodegradation of Polystyrene by Environmental Microorganisms
    materials Communication Potential for and Distribution of Enzymatic Biodegradation of Polystyrene by Environmental Microorganisms Liyuan Hou and Erica L.-W. Majumder * Department of Chemistry, SUNY College of Environmental Science and Forestry, Syracuse, NY 13210, USA; [email protected] * Correspondence: [email protected] or [email protected]; Tel.: +1-3154706854 Abstract: Polystyrene (PS) is one of the main polymer types of plastic wastes and is known to be resistant to biodegradation, resulting in PS waste persistence in the environment. Although previous studies have reported that some microorganisms can degrade PS, enzymes and mechanisms of microorganism PS biodegradation are still unknown. In this study, we summarized microbial species that have been identified to degrade PS. By screening the available genome information of microorganisms that have been reported to degrade PS for enzymes with functional potential to depolymerize PS, we predicted target PS-degrading enzymes. We found that cytochrome P4500s, alkane hydroxylases and monooxygenases ranked as the top potential enzyme classes that can degrade PS since they can break C–C bonds. Ring-hydroxylating dioxygenases may be able to break the side-chain of PS and oxidize the aromatic ring compounds generated from the decomposition of PS. These target enzymes were distributed in Proteobacteria, Actinobacteria, Bacteroidetes, and Firmicutes, suggesting a broad potential for PS biodegradation in various earth environments and microbiomes. Our results provide insight into the enzymatic degradation of PS and suggestions for realizing the biodegradation of this recalcitrant plastic. Citation: Hou, L.; Majumder, E.L. Keywords: plastics; polystyrene biodegradation; enzymatic biodegradation; monooxygenase; alkane Potential for and Distribution of hydroxylase; cytochrome P450 Enzymatic Biodegradation of Polystyrene by Environmental Microorganisms.
    [Show full text]
  • Pluralibacter Gergoviae Als Spender- Oder Empfängerorganismus Gemäß § 5 Absatz 1 Gentsv
    Az. 45241.0205 Juni 2020 Empfehlung der ZKBS zur Risikobewertung von Pluralibacter gergoviae als Spender- oder Empfängerorganismus gemäß § 5 Absatz 1 GenTSV Allgemeines Pluralibacter gergoviae (früher: Enterobacter gergoviae [1]) ist ein Gram-negatives, fakultativ anaerobes, peritrich begeißeltes, stäbchenförmiges Bakterium aus der Familie der Enterobacteriaceae, das zuerst 1980 beschrieben wurde [2]. Es ist weltweit verbreitet und wurde aus klinischen Proben (Blut, Urin, Sputum, Stuhl, Hautabstriche, Ohrendrainage, nicht näher beschriebene Wunden, Abszesse, Lunge, Niere) sowie aus dem Darm eines Roten Baumwollkapselwurms, Wasserproben und Kosmetikprodukten isoliert [2–7]. Das Überleben in Kosmetikprodukten wird dadurch ermöglicht, dass P. gergoviae eine hohe Toleranz gegen Konservierungsmittel wie Benzoesäure und Parabenen aufweist [8]. Aufgrund dieser Toleranz ist P. gergoviae in der Vergangenheit mehrfach als mikrobielle Verunreinigung in Kosmetikprodukten aufgetreten, die daraufhin zurückgerufen werden mussten [9]. Im klinischen Kontext tritt P. gergoviae vergleichsweise selten als Krankheitserreger auf. Das Bakterium löst vor allem bei Immunkompromittierten Infektionen aus, die tödlich verlaufen können. Es verursachte Harnwegsinfektionen oder Infektionen der Operationswunde bei Empfängern von Nierentransplantaten [10], mehrere Sepsisfälle auf einer Neugeborenenstation, von denen die Mehrzahl Frühgeborene betrafen [3], und führte zu einem Septischen Schock bei einem Leukämie-Patienten [11]. Bei Immunkompetenten wurden eine Sepsis
    [Show full text]
  • Non-Commercial Use Only
    Infectious Disease Reports 2020; volume 12:8376 Peritonitis from facultative presenting with Citrobacter freundii peri- anaerobic gram-negative bacilli tonitis. Correspondence: Sreedhar Adapa, The Citrobacter freundii (C. freundii) is a Nephrology Group, 568 East Herndon Avenue likely due to translocation of motile, facultative anaerobe, non-sporing #201, Fresno, CA 93720, USA. bacteria from gut in a patient gram-negative bacilli colonize in the gas- Tel.: 5592286600 - Fax: 5592263709. undergoing peritoneal dialysis trointestinal tract of humans and other ani- E-mail: [email protected] mals. It is also found in water, soil, and Key words: Citrobacter freundii, peritonitis, food.1 Werkman and Gillen discovered Sreedhar Adapa,1 Srikanth Naramala,2 SPICE organisms, peritoneal dialysis. 3 genus Citrobacter in 1932 and the organism Harmandeep Singh Tiwana, uses citrate a sole carbon source for the Contributions: All authors contributed equally 4 4 Niraj Patel, Raman Verma, energy source and hence derives its name.2 to the text of the manuscript and the literature 5 Narayana Murty Koduri, Venu Madhav C. freundii is hydrogen sulfide positive, review. SA was responsible for the original Konala6 indole negative, adonitol negative, and mal- diagnosis and treatment. Manuscript prepara- 3 tion and modification by VM. 1The Nephrology group, Fresno, CA; onate negative in character. Peritonitis 2 Department of Rheumatology, from gram-negative organisms frequently Conflict of interest: The authors declare no Adventist Medical Center, Hanford, CA; results in hospitalization, catheter loss, dial- potential conflict of interest. 3 ysis modality change, and mortality. These Department of Internal Medicine, infections are hard to treat because of Funding: None. Adventist Medical Center, Hanford, CA; biofilm formation, which makes them less 4Department of Internal Medicine, susceptible to antibiotics.
    [Show full text]
  • Upper and Lower Case Letters to Be Used
    Isolation, characterization and genome sequencing of a soil-borne Citrobacter freundii strain capable of detoxifying trichothecene mycotoxins by Rafiqul Islam A Thesis Presented to The University of Guelph In Partial Fulfilment of Requirements for the Degree of Doctor of Philosophy in Plant Agriculture Guelph, Ontario, Canada © Rafiqul Islam, April, 2012 ABSTRACT ISOLATION, CHARACTERIZATION AND GENOME SEQUENCING OF A SOIL- BORNE CITROBACTER FREUNDII STRAIN CAPABLE OF DETOXIFIYING TRICHOTHECENE MYCOTOXINS Rafiqul Islam Advisors: University of Guelph, 2012 Dr. K. Peter Pauls Dr. Ting Zhou Cereals are frequently contaminated with tricthothecene mycotoxins, like deoxynivalenol (DON, vomitoxin), which are toxic to humans, animals and plants. The goals of the research were to discover and characterize microbes capable of detoxifying DON under aerobic conditions and moderate temperatures. To identify microbes capable of detoxifying DON, five soil samples collected from Southern Ontario crop fields were tested for the ability to convert DON to a de-epoxidized derivative. One soil sample showed DON de-epoxidation activity under aerobic conditions at 22-24°C. To isolate the microbes responsible for DON detoxification (de-epoxidation) activity, the mixed culture was grown with antibiotics at 50ºC for 1.5 h and high concentrations of DON. The treatments resulted in the isolation of a pure DON de-epoxidating bacterial strain, ADS47, and phenotypic and molecular analyses identified the bacterium as Citrobacter freundii. The bacterium was also able to de-epoxidize and/or de-acetylate 10 other food-contaminating trichothecene mycotoxins. A fosmid genomic DNA library of strain ADS47 was prepared in E. coli and screened for DON detoxification activity. However, no library clone was found with DON detoxification activity.
    [Show full text]
  • CATALOGO GENERALE - Listino Prezzi 2020 2021 Chromart CATALOGOTERRENI GENERALE Listinocromogeni Prezzi 2021 - 2022 Per La Microbiologia Industriale
    Microbiologia Microbiologia Microbiologia Microbiologia Microbiologia Microbiologia CATALOGO GENERALE - Listino Prezzi 2020 2021 CATALOGO ChromArt CATALOGOTERRENI GENERALE ListinoCROMOGENI Prezzi 2021 - 2022 Per la Microbiologia Industriale Microbiologia Clinica e Industriale Ph: A. Geraci Microbiologia Clinica e Industriale Terreni cromogeni Rev. 02/2021 per l’isolamento e l’identificazione dei principali patogeni ed indicatori fecali negli alimenti, mangimi ed acque. Biolife Biolife ItalianaBiolife srl - VItalianaiale Monza srl - 272Viale 20128 Monza Milano272 20128 - Tel. 02Milano 25209.1 - Tel. 02- www 25209.1.biolifeitaliana.i - www.biolifeitaliana.it t Biolife Italiana srl - Viale Monza 272 20128 Milano - Tel. 02 25209.1 - www.biolifeitaliana.it t .biolifeitaliana.i www - 25209.1 02 l. Te - Milano 20128 272 Monza iale V - l sr Italiana Biolife CONDIZIONI GENERALI DI VENDITA PREZZI I prezzi segnati nei nostri listini si intendono Iva esclusa e sono comprensivi di imballo normale e spedizione con vettori con noi convenzionati. Gli imballi speciali e/o refrigerati saranno addebitati al costo. Le spedizioni con vettori scelti dal cliente saranno a carico di quest’ultimo. L’IVA (Imposta sul Valore Aggiunto) è sempre a carico del Committente nella misura di legge. ORDINI Gli ordini devono essere formulati per iscritto e verranno evasi rispettando le unità di confezioni indicate nel listino. Per evitare errori raccomandiamo di indicare sempre negli ordini il numero di codice e la denominazione di ciascun articolo nonché la quantità richiesta. È nostro diritto accettare, annullare e procrastinare in tutto o in parte ordini a seguito di sopravvenute impossibilità da parte nostra, dei nostri fornitori e dei vettori. Tali cause ci sollevano da ogni obbligo precedentemente assunto con l’accettazione dell’ordine.
    [Show full text]
  • Uncommon Pathogens Causing Hospital-Acquired Infections in Postoperative Cardiac Surgical Patients
    Published online: 2020-03-06 THIEME Review Article 89 Uncommon Pathogens Causing Hospital-Acquired Infections in Postoperative Cardiac Surgical Patients Manoj Kumar Sahu1 Netto George2 Neha Rastogi2 Chalatti Bipin1 Sarvesh Pal Singh1 1Department of Cardiothoracic and Vascular Surgery, CN Centre, All Address for correspondence Manoj K Sahu, MD, DNB, Department India Institute of Medical Sciences, Ansari Nagar, New Delhi, India of Cardiothoracic and Vascular Surgery, CTVS office, 7th floor, CN 2Infectious Disease, Department of Medicine, All India Institute of Centre, All India Institute of Medical Sciences, New Delhi-110029, Medical Sciences, Ansari Nagar, New Delhi, India India (e-mail: [email protected]). J Card Crit Care 2020;3:89–96 Abstract Bacterial infections are common causes of sepsis in the intensive care units. However, usually a finite number of Gram-negative bacteria cause sepsis (mostly according to the hospital flora). Some organisms such as Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus are relatively common. Others such as Stenotrophomonas maltophilia, Chryseobacterium indologenes, Shewanella putrefaciens, Ralstonia pickettii, Providencia, Morganella species, Nocardia, Elizabethkingia, Proteus, and Burkholderia are rare but of immense importance to public health, in view of the high mortality rates these are associated with. Being aware of these organisms, as the cause of hospital-acquired infections, helps in the prevention, Keywords treatment, and control of sepsis in the high-risk cardiac surgical patients including in ► uncommon pathogens heart transplants. Therefore, a basic understanding of when to suspect these organ- ► hospital-acquired isms is important for clinical diagnosis and initiating therapeutic options. This review infection discusses some rarely appearing pathogens in our intensive care unit with respect to ► cardiac surgical the spectrum of infections, and various antibiotics that were effective in managing intensive care unit these bacteria.
    [Show full text]
  • 경추 척수 손상 환자에서 발생한 Providencia Rettgeri 패혈증 1예 조현정·임승진·천승연·박권오·이상호·박종원·이진서·엄중식 한림대학교 의과대학 내과학교실
    Case Report Infection & DOI: 10.3947/ic.2010.42.6.428 Chemotherapy Infect Chemother 2010;42(6):428-430 경추 척수 손상 환자에서 발생한 Providencia rettgeri 패혈증 1예 조현정·임승진·천승연·박권오·이상호·박종원·이진서·엄중식 한림대학교 의과대학 내과학교실 A Case of Providencia rettgeri Sepsis in a Patient with Hyun-Jung Cho, Seung-Jin Lim, Seung-Yeon Chun, Cervical Cord Injury Kwon-Oh Park, Sang-Ho Lee, Jong-Won Park, Jin- Seo Lee, and Joong-Sik Eom Providencia rettgeri is a member of Enterobacteriacea that is known to cause Department of Internal Medicine, Hallym Univer- urinary tract infection (UTI), septicemia, and wound infections, especially in sity College of Medi cine, Seoul, Korea immunocompromised patients and in those with indwelling urinary catheters. We experienced a case of UTI sepsis by Providencia rettgeri in a patient with spinal cord injury. The patient had only high fever without urinary symptoms or signs after high dose intravenous methylprednisolone. The laboratory results showed leukocytosis (21,900/μL, segmented neutrophils 91.1%) and pyuria. Cefepime was given empirically and it was switched to oral trimethoprim-sulfamethoxazole because P. rettgeri was identified from blood and urine culture which was susceptible to TMP-SMX. The patient was improved clinically but P. rettgeri was not eradicated microbiologically. To the best of our knowledge, this is the first case report on sepsis caused by Providencia rettgeri in Korea. Key Words: Providencia rettgeri, Sepsis, Urinary tract infection Introduction The genus Providencia is a member of the Enterobacteriaceae family which commonly dwells in soil, water, and sewage [1, 2]. Providencia rettgeri is one of five Providencia species that is known to cause various infections, especially the Copyright © 2010 by The Korean Society of Infectious Diseases | Korean urinary tract infection (UTI) [3].
    [Show full text]
  • In Vitro Activities of Aztreonam-Avibactam and Ceftazidime-Avibactam Against Less Commonly Encountered Gram-Negative Bacteria Co
    IHMA, Inc. In Vitro Activities of Aztreonam-avibactam and Ceftazidime-avibactam Against Less Commonly Encountered Gram-Negative 2122 Palmer Drive P1155 Schaumburg, IL 60173 USA Bacteria Collected During the ATLAS Global Surveillance Program 2012-2017 www.ihma.com M. Hackel1, G Stone2, B. deJonge3, D. Sahm1 1IHMA, Inc., Schaumburg IL, USA 2Pfizer Inc., Cambridge, MA USA 3Pfizer Inc., Cambridge MA, USA Introduction Results Results While antimicrobial susceptibility Table 1. Less commonly isolated gram-negative species Table 2. In vitro activity of ceftazidime-avibactam, aztreonam-avibactam and comparators against less commonly encountered gram-negative bacteria collected in 2012-2017 . ATM-AVI and CAZ-AVI showed MIC90 values from the ATLAS Global Surveillance Program 2012-2017 AZT-AVI CAZ-AVI CST* MEM TGC TZP LVX profiles have been well described in Organism N ranging from ≤0.015 to 0.5 mg/L and 0.06 to 1 %S MIC Range %S MIC Range %S MIC Range %S MIC Range %S MIC Range %S MIC Range %S MIC Range more common members of the 90 90 90 90 90 90 90 mg/L, respectively, against members of the Organism N Percent of total Acinetobacter nosocomialis 183 na 64 2 - >128 na 32 1 - >128 96.8 2 0.25 - >8 79.8 > 8 0.015 - >8 na 1 0.06 - 4 na > 128 ≤0.25 - >128 76.5 >4 0.06 - >8 Enterobacterales, notably Escherichia Enterobacterales (Table 2). 98.3% were coli and Klebsiella pneumoniae, and in Acinetobacter nosocomialis 183 5.1 Acinetobacter pittii 402 na 64 2 - >128 na 16 0.5 - >128 99.2 2 0.12 - 4 92.3 1 ≤0.06 - >8 na 1 0.03 - >8 na 64 ≤0.25 - >128 88.6 2 0.06 - >8 Citrobacter spp.
    [Show full text]
  • Citrobacter Braakii
    & M cal ed ni ic li a l C G f e Trivedi et al., J Clin Med Genom 2015, 3:1 o n l o a m n r DOI: 10.4172/2472-128X.1000129 i u c s o Journal of Clinical & Medical Genomics J ISSN: 2472-128X ResearchResearch Article Article OpenOpen Access Access Phenotyping and 16S rDNA Analysis after Biofield Treatment on Citrobacter braakii: A Urinary Pathogen Mahendra Kumar Trivedi1, Alice Branton1, Dahryn Trivedi1, Gopal Nayak1, Sambhu Charan Mondal2 and Snehasis Jana2* 1Trivedi Global Inc., Eastern Avenue Suite A-969, Henderson, NV, USA 2Trivedi Science Research Laboratory Pvt. Ltd., Chinar Fortune City, Hoshangabad Rd., Madhya Pradesh, India Abstract Citrobacter braakii (C. braakii) is widespread in nature, mainly found in human urinary tract. The current study was attempted to investigate the effect of Mr. Trivedi’s biofield treatment on C. braakii in lyophilized as well as revived state for antimicrobial susceptibility pattern, biochemical characteristics, and biotype number. Lyophilized vial of ATCC strain of C. braakii was divided into two parts, Group (Gr.) I: control and Gr. II: treated. Gr. II was further subdivided into two parts, Gr. IIA and Gr. IIB. Gr. IIA was analysed on day 10 while Gr. IIB was stored and analysed on day 159 (Study I). After retreatment on day 159, the sample (Study II) was divided into three separate tubes. First, second and third tube was analysed on day 5, 10 and 15, respectively. All experimental parameters were studied using automated MicroScan Walk-Away® system. The 16S rDNA sequencing of lyophilized treated sample was carried out to correlate the phylogenetic relationship of C.
    [Show full text]
  • The LOUISIANA ANTIBIOGRAM Louisiana Antibiotic Resistance 2014
    The LOUISIANA ANTIBIOGRAM Louisiana Antibiotic Trends in Antibiotic Resistance Resistance 2014 in Louisiana 2008 Zahidul Islam MBBS, MPH, Raoult C Ratard MD MPH Contributors to this report: Lauren Kleamenakis MPH, Anup Subedee MD MPH and Raoult Ratard MD MPH. This report covers bacteria causing severe human infections and the antibiotics used to treat those infections. Resistance to other antimicrobials (antivirals, antifungals and anti-parasitic drugs) are not included for lack of systematic reporting and collection of comprehensive data. Contents 1-Introduction ............................................................................................................................................... 3 1.1-Bacterial resistance to antibiotics is a major threat to human health .................................................. 3 1.2-Tracking resistance patterns is a major action in the fight against antibiotic resistance ..................... 3 2-Methods ..................................................................................................................................................... 3 2.1-Active surveillance .............................................................................................................................. 3 2.2-Antibiogram collection ....................................................................................................................... 3 2.3-Analysis ..............................................................................................................................................
    [Show full text]
  • Pocket Guide to Clinical Microbiology
    4TH EDITION Pocket Guide to Clinical Microbiology Christopher D. Doern 4TH EDITION POCKET GUIDE TO Clinical Microbiology 4TH EDITION POCKET GUIDE TO Clinical Microbiology Christopher D. Doern, PhD, D(ABMM) Assistant Professor, Pathology Director of Clinical Microbiology Virginia Commonwealth University Health System Medical College of Virginia Campus Washington, DC Copyright © 2018 Amer i can Society for Microbiology. All rights re served. No part of this publi ca tion may be re pro duced or trans mit ted in whole or in part or re used in any form or by any means, elec tronic or me chan i cal, in clud ing pho to copy ing and re cord ing, or by any in for ma tion stor age and re trieval sys tem, with out per mis sion in writ ing from the pub lish er. Disclaimer: To the best of the pub lish er’s knowl edge, this pub li ca tion pro­ vi des in for ma tion con cern ing the sub ject mat ter cov ered that is ac cu rate as of the date of pub li ca tion. The pub lisher is not pro vid ing le gal, med i cal, or other pro fes sional ser vices. Any ref er ence herein to any spe cific com mer cial prod ucts, pro ce dures, or ser vices by trade name, trade mark, man u fac turer, or oth er wise does not con sti tute or im ply en dorse ment, rec om men da tion, or fa vored sta tus by the Ameri can Society for Microbiology (ASM).
    [Show full text]